Valiance

Valiance is a London-based growth-oriented MedTech investor that aggressively funds advanced cardiovascular devices and hardware innovations across Europe. The firm concentrates on medical devices and diagnostics, two capital-intensive subsectors where regulatory pathways, clinical evidence generation, and manufacturing scale-up dictate company strategy. Founders building Class II and Class III devices, structural heart technologies, imaging-adjacent diagnostics, and specialty hardware platforms are the natural audience. AI is not a stated focus, though software components inside device platforms are consistent with the thesis.

Valiance writes Series A through Series C checks in the $5M to $25M range, positioning itself as a meaningful lead or co-lead in mid-stage rounds rather than a small follow-on. The geographic mandate is European, with the London base providing access to UK clinical centers, Continental engineering hubs, and the wider European regulatory environment. Companies should typically have a working device, early clinical data or active studies, and a credible path through CE marking and reimbursement to engage productively. The check sizes suggest Valiance expects ownership levels and board involvement consistent with growth-stage device investing.

Named partners and a detailed portfolio list are not specified in the materials reviewed, so this profile reflects limited public information about the team and historical investments. Founders should prepare a clear clinical and regulatory roadmap, manufacturing strategy, and reimbursement narrative. Outreach is most productive when the company has crossed first-in-human or pivotal-readiness milestones, since Valiance’s check size and stage focus map most cleanly to teams pursuing pivotal trials, commercial launch, and market expansion across multiple European geographies.